In Clinical Practice, Drug-Eluting Stents Outperform Bare-Metal Stents

In a population-based cohort, DES resulted in fewer repeat revascularizations than BMS, with no difference in rates of death or MI at 1 year.

Recent reports have raised concerns about late stent thrombosis with the use of drug-eluting stents (DES), particularly for off-label indications. In this National Heart, Lung, and Blood Institute Dynamic Registry analysis, investigators compared outcomes in 1763 patients who received at least one DES (for an on-label or off-label indication) with outcomes in 1460 patients who received at least one bare-metal stent (BMS) shortly before DES became routinely available.

The BMS recipients were less likely to have diabetes and other cardiac risk factors and more likely to have acute MI than the DES recipients. Although reference vessel diameter was similar in the two groups, more BMS recipients had total occlusions and bifurcation lesions, and m…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)